The USA: FDA is holding back the enforcement of certain UDI requirements

2024-02-29T14:46:51+00:00July 1st, 2020|Categories: Compliance, Covid-19, Regulatory, USA|Tags: , , |

The US Food and Drug Administration (FDA) has published final guidance for unique device identification compliance dates for Class I and Unclassified Medical Devices. This immediately in effect guidance also clarifies the Agency policy concerning compliance dates for certain [...]

Czech Republic: Opinion of the SÚKL Department of Clinical Trials on ongoing clinical trials and on clinical trials not yet initiated in relation to COVID-19

2024-02-02T10:24:34+00:00June 30th, 2020|Categories: Clinical Trial, Covid-19, Eastern Europe, Europe, Regulatory|Tags: , , , |

The Czech Authority State Institute for Drug Control (SÚKL) updated its general recommendations respecting the current epidemiological situation with coronavirus regarding ongoing or not yet started clinical trials and the release of emergency measures of the government. This opinion [...]

US: FDA published Q&A guidance on the effects of the COVID-19 emergency on formal meetings and user fee applications for medical devices

2024-02-29T17:05:07+00:00June 24th, 2020|Categories: Clinical Trial, Covid-19, Regulatory, USA|Tags: , , , , |

FDA published a Q&A document to respond frequently asked questions from submitters and applicants on regulatory matters and issues relating to medical devices arising from  the COVID-19 public health emergency. This guidance addresses the following: Meetings with Industry MDUFA [...]

FDA provides statistical guidance for trials during COVID-19

2024-02-26T09:26:25+00:00June 18th, 2020|Categories: Clinical Trial, Compliance, Covid-19, USA|Tags: , , , |

The FDA issued guidance to provide sponsors with statistical advice in order to maintain trial integrity and reduce the impact of the COVID-19 emergency on clinical trials conduct. This new document follows the agency’s guidances on the conduct of [...]

MDCG issued guidance on transitioning devices with ancillary substances to MDR

2024-02-26T16:44:18+00:00June 12th, 2020|Categories: Compliance, Covid-19, Europe, MDR, Regulatory|Tags: , , , |

The European Commission’s Medical Device Coordination Group (MDCG)  released guidance about the process for transitioning CE certificates for devices carrying ancillary substance which could be considered a medicinal product and those incorporating animal tissues to the MDR. Ancillary substances [...]

USA: FDA issued guidance for remote patient monitoring devices used during COVID-19

2024-02-29T17:13:19+00:00June 9th, 2020|Categories: Covid-19, Regulatory, USA|Tags: , , , |

FDA issued "guidance to provide a policy to help expand the availability and capability of non-invasive remote monitoring devices to facilitate patient monitoring while reducing patient and healthcare provider contact and exposure to COVID-19 for the duration of the [...]

European Commission updates on MDR and IVDR implementation timeline

2024-02-07T15:50:33+00:00June 9th, 2020|Categories: Compliance, Covid-19, Europe, MDR, Regulatory|Tags: , , , |

The European Commission updated its “rolling plan” for adopting implementing acts and other actions/initiatives ahead of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). The update follows the delay of implementation of the MDR by one [...]

Spain: Monitoring visits in hospitals allowed again

2024-02-29T14:18:56+00:00June 8th, 2020|Categories: Clinical Trial, Covid-19, Europe, Western Europe|Tags: , , |

Good news from Spain! Our monitors informed us about the restart of onsite monitoring visits as of today June 8th, 2020 after the break imposed by the COVID-19 emergency. Meditrial is closely monitoring the situation in all countries to restart [...]

UK: MHRA provides regulatory guidance on software used in the diagnosis, treatment and management of  COVID-19 patients

2024-02-29T16:23:25+00:00June 8th, 2020|Categories: Covid-19, Regulatory, UK|Tags: , , |

MHRA provided advice for manufacturers, members of the public and professional users of software or apps being used during the COVID-19 pandemic. Standalone software and apps that meet the definition of a medical device are required to be CE [...]

UK: The MHRA provides regulatory flexibilities resulting from COVID-19

2024-02-29T16:31:53+00:00June 8th, 2020|Categories: Clinical Trial, Covid-19, Europe, UK|Tags: , , , |

The MHRA updated its Guidance for industry on flexible approaches to regulation they are taking during the COVID-19 outbreak. In the last update from 5th June 2020, the Agency added information on audits of Notified Bodies and manufacturers in [...]

Go to Top